CIRCULOGENE molecular diagnostics laboratory, a subcontractor to Geneva, which has been awarded a $1.5M U.S. Department of Defense grant, is to develop liquid biopsy markers for the rapid and accurate assessment of traumatic brain injury (TBI). The Defense Medical Research and Development Program Precision Trauma Care Research Award is to support research applying precision medicine concepts to trauma care. Geneva researcher and employee Dr. Andriy Batchinsky will be working on this study to test treatment options and improve survival rates in severely wounded military and civilian personnel.
TBI, alone and in combination with polytrauma and lung injury, causes the vast majority of combat-related deaths. In recent conflicts, more than 80 percent of wounded U.S. service members had some form of TBI complicated with trauma to the chest and bleeding, leading to severe combined injuries and acute lung failure.
“As one of the leading molecular diagnostics laboratories in the world, we are proud to have been selected as a partner for this project,” said CIRCULOGENE CEO Mike Mullen. “This award recognizes our proprietary, in situ, cell-free DNA (cfDNA) quantification process, which will be key in helping researchers identify and measure circulating markers of TBI and other battlefield trauma.”
To learn more about this partnership and the outlined research, read the full press release here.